Federico, Leonardo Bruno published the artcileIdentification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening, COA of Formula: C18H19Cl2NO4, the main research area is SARSCoV2 mpro inhibitor ligand screening; COVID-19; SARS-CoV-2; drug repositioning; ligand-based drug discovery; main-protease (Mpro); structure-based drug discovery.
Background: The new coronavirus pandemic has had a significant impact worldwide, and therapeutic treatment for this viral infection is being strongly pursued. Efforts have been undertaken by medicinal chemists to discover mols. or known drugs that may be effective in COVID-19 treatment – in particular, targeting the main protease (Mpro) of the virus. Materials & methods: We have employed an innovative strategy – application of ligand- and structure-based virtual screening – using a special compilation of an approved and diverse set of SARS-CoV-2 crystallog. complexes that was recently published. Results and conclusion: We identified seven drugs with different original indications that might act as potential Mpro inhibitors and may be preferable to other drugs that have been repurposed. These drugs will be exptl. tested to confirm their potential Mpro inhibition and thus their effectiveness against COVID-19.
Future Medicinal Chemistry published new progress about Antiviral agents. 72509-76-3 belongs to class pyridine-derivatives, name is 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C18H19Cl2NO4, COA of Formula: C18H19Cl2NO4.